Schwartz Jonathan David (CIK 1726398) reported 7 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2025-11-20). Recent activity: Sell RCKT (2,545 shares), Buy RCKT (80,000 shares), Sell RCKT (1,680 shares), Sell RCKT (805 shares), Sell RCKT (11,161 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-20 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Science & Gene Therapy Officer | Sell | 2,545 | $7,584 |
| 2025-09-09 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Medical & Gene Therapy Officer | Buy | 80,000 | $0 |
| 2025-08-20 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Medical & Gene Therapy Officer | Sell | 1,680 | $5,158 |
| 2025-08-20 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Medical & Gene Therapy Officer | Sell | 805 | $2,415 |
| 2025-08-18 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Medical & Gene Therapy Officer | Sell | 11,161 | $33,706 |
| 2025-05-22 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Medical & Gene Therapy Officer | Sell | 801 | $5,166 |
| 2025-05-20 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Chief Medical & Gene Therapy Officer | Sell | 1,582 | $10,330 |
来源：SEC Form 4 申报文件 · 截至 2025-11-20